[
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, in cancer patients, the principal contributors to cfDNA are the components of the tumor microenvironment (TME), which include tumor cells and tumor-infiltrating T lymphocytes (30) (\nFigure 1\n).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is anticipated that these markers will see expanded adoption in clinical settings in the foreseeable future, paving the way for broader clinical utilization (\nFigure 2\n).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "As a result, ctDNA has the potential to make significant contributions in various aspects of breast cancer management, including screening, diagnosis, prognosis, treatment, and follow-up (\nFigure 3\n).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]